Profound Medical Corp
TSX:PRN

Watchlist Manager
Profound Medical Corp Logo
Profound Medical Corp
TSX:PRN
Watchlist
Price: 10.03 CAD 0.3% Market Closed
Market Cap: 247.4m CAD
Have any thoughts about
Profound Medical Corp?
Write Note

Profound Medical Corp
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Profound Medical Corp
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Profound Medical Corp
TSX:PRN
Research & Development
-$16.2m
CAGR 3-Years
-15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Research & Development
$14k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Research & Development
-CA$11.3m
CAGR 3-Years
-28%
CAGR 5-Years
-25%
CAGR 10-Years
-20%
Theralase Technologies Inc
XTSX:TLT
Research & Development
-CA$2.6m
CAGR 3-Years
-17%
CAGR 5-Years
-3%
CAGR 10-Years
-15%
MedMira Inc
XTSX:MIR
Research & Development
-CA$476.9k
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-5%
O
Ondine Biomedical Inc
LSE:OBI
Research & Development
-CA$5.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Profound Medical Corp
Glance View

Market Cap
247.4m CAD
Industry
Health Care

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRN Intrinsic Value
5.75 CAD
Overvaluation 43%
Intrinsic Value
Price

See Also

What is Profound Medical Corp's Research & Development?
Research & Development
-16.2m USD

Based on the financial report for Sep 30, 2024, Profound Medical Corp's Research & Development amounts to -16.2m USD.

What is Profound Medical Corp's Research & Development growth rate?
Research & Development CAGR 3Y
-15%

Over the last year, the Research & Development growth was -20%. The average annual Research & Development growth rates for Profound Medical Corp have been -15% over the past three years .

Back to Top